Absci (ABSI) vs Mineralys Therapeutics (MLYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Absci (ABSI) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 153.4% versus a loss of 40.7%. Mineralys Therapeutics is the larger company by market cap ($2.07 billion vs $1.74 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | MLYS |
|---|---|---|
| Share price | $10.16 | $23.37 |
| Market cap | $1.74B | $2.07B |
| 1-day change | +13.65% | +4.42% |
| YTD return | +191.12% | -35.60% |
| 1-year return | +153.37% | -40.67% |
| 5-year return | -4.42% | — |
| EPS (TTM) | $-0.79 | $-4.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | — |
| Revenue growth (YoY) | -38.24% | — |
| Net income (latest FY) | $-115.18M | $-154.65M |
| Operating margin | -4297.04% | — |
| Net margin | -4113.68% | — |
| 52-week high | $12.06 | $47.65 |
| 52-week low | $2.24 | $21.46 |
| Distance from 52-week high | -15.72% | -50.95% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +41.73% | +107.53% |
| Average volume | 3.43M | 1.04M |
| Shares outstanding | 171.61M | 88.41M |
| Employees | 140 | 76 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABSI has outperformed MLYS by 194.0 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Healthcare · Biotechnology · 140 employees
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Healthcare · Biotechnology · 76 employees
ABSI vs MLYS FAQ
Which is bigger, Absci or Mineralys Therapeutics?
Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $2.07B compared with $1.74B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or MLYS?
ABSI returned +153.37% over the past 12 months, compared with -40.67% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Mineralys Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.